Arrowhead Pharmaceuticals, Inc. (0HI3.L)

23,91 +0,22 (+0,92%) Alla chiusura: 08:08PM BST

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
https://arrowheadpharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 397

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Christopher R. Anzalone Ph.D.	CEO, Pres & Director	1,65M	996,46k	1969
Mr. Kenneth A. Myszkowski	Chief Financial Officer	761,55k	N/D	1966
Mr. Patrick O'Brien J.D., PharmD	COO, Gen. Counsel & Sec.	749,86k	172,2k	1964
Dr. James C. Hamilton M.D., MBA	Chief of Discovery & Translational Medicine	676,81k	N/D	1978
Ms. Tracie Oliver	Chief Commercial Officer	449,58k	N/D	N/D
Dr. Mark M. Davis Ph.D.	Founder and Founder & Director of Insert Therapeutics Inc & Calando	N/D	N/D	N/D
Dr. Vincent Anzalone CFA	Head of Investor Relations & VP	N/D	N/D	N/D
Mr. Howard Lovy	Director of Communications	N/D	N/D	N/D
Dr. Mark Seefeld	Head of Toxicology & VP	N/D	N/D	1954
Dr. Javier San Martin M.D.	Chief Medical Officer	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Governance aziendale

L'ISS Governance QualityScore di Arrowhead Pharmaceuticals, Inc. al 1 marzo 2023 è 3. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 1; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.